Compare SDHC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDHC | EVO |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.3M | 934.1M |
| IPO Year | 2023 | N/A |
| Metric | SDHC | EVO |
|---|---|---|
| Price | $10.83 | $2.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $14.60 | $7.00 |
| AVG Volume (30 Days) | 77.5K | ★ 91.4K |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $971,116,000.00 | N/A |
| Revenue This Year | $4.21 | $1.37 |
| Revenue Next Year | $11.07 | $10.05 |
| P/E Ratio | $181.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.81 | $2.31 |
| 52 Week High | $23.50 | $4.80 |
| Indicator | SDHC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 34.35 | 42.25 |
| Support Level | $11.18 | $2.63 |
| Resistance Level | $15.45 | $3.36 |
| Average True Range (ATR) | 0.68 | 0.08 |
| MACD | -0.20 | -0.05 |
| Stochastic Oscillator | 13.91 | 22.16 |
Smith Douglas Homes Corpis a builder of single-family homes in communities in certain markets in the southeastern and southern United States. The Company's homes and communities are targeted to first-time and empty-nest homebuyers. The Company currently operates in metropolitan Atlanta, Birmingham, Chattanooga, Central Georgia, Charlotte, Dallas-Fort Worth, Greenville, Alabama Gulf Coast, Huntsville, Nashville, Raleigh and Houston. Its operations are currently organized into ten geographical divisions which comprise two reportable segments. Its Southeast segment consists of its Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of its Alabama, Dallas-Fort Worth, Houston, Nashville, and Alabama Gulf Coast divisions.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.